Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.12), $0.11 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $37.85 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.